STF-62247

Research use only, not for human use.

STF-62247 is a small molecule Autophagy inducer that induces autophagy and selectively induces lethality in VHL-deficient RCC cells.

STF-62247 is a small molecule Autophagy inducer that induces autophagy and selectively induces lethality in VHL-deficient RCC cells; induces cytotoxicity and reduces tumor growth in VHL-deficient cells in a HIF-independent manner, PI3K and Golgi trafficking are required as initial signals in STF-62247-induced autophagy.Kidney Cancer Preclinical.

In RCC4, RCC4/VHL, SN12C, SN12C-VHL shRNA cells, STF-62247 (0-30 μM) is selectively toxic to VHL-deficient cells compared to their VHL wild-type counterparts.STF-62247-treated cells accumulated intracytoplasmic vacuoles characteristic of cells undergoing autophagy. Moreover, these vacuoles are larger in VHL-deficient RCC4 and SN12C-VHL shRNA cells than in wild-type VHL cells.

STF-62247 (2.7-8 mg/kg; intraperitoneal injection; daily; for 9 days) treatment significantly reduces tumor growth of VHL-deficient cells. Animal Model:SCID mice implanted with SN12C-VHL shRNA cells Dosage:2.7 mg/kg, or 8 mg/kg Administration:Intraperitoneal injection; daily; for 9 days Result:Significantly reduced tumor growth of VHL-deficient cells.

STF62247 | STF 62247

Autophagy

Autophagy

ER

Cancer

Kidney Cancer

315702-99-9

267.3488

C15H13N3S

>98% (HPLC)

DMSO: ≥ 31 mg/mL

CC1=CC(NC2=NC(C3=CC=NC=C3)=CS2)=CC=C1

2-Thiazolamine, N-(3-methylphenyl)-4-(4-pyridinyl)-

(-20℃)

With Ice Pack

≥ 2 years